ABL1 is an inclusion eligibility criterion in 2 clinical trials for T-cell prolymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain ABL1 status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [3].

AFF1 is an inclusion eligibility criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains AFF1 status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

BCR is an inclusion eligibility criterion in 2 clinical trials for T-cell prolymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain BCR status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [3].

DEK is an inclusion eligibility criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains DEK status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

ELL is an inclusion eligibility criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains ELL status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains FGFR3 status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (0 open) [3].

FLT3 is an inclusion eligibility criterion in 3 clinical trials for T-cell prolymphocytic leukemia, of which 1 is open and 2 are closed. Of the trials that contain FLT3 status and T-cell prolymphocytic leukemia as inclusion criteria, 2 are phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [3].

IGH is an inclusion eligibility criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains IGH status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (0 open) [3].

KMT2A is an inclusion eligibility criterion in 2 clinical trials for T-cell prolymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain KMT2A status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [3].

MAF is an inclusion eligibility criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains MAF status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (0 open) [3].

MECOM is an inclusion eligibility criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains MLLT1 status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains MLLT10 status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains MLLT3 status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains MLLT4 status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains NRIP3 status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

NUP214 is an inclusion eligibility criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains NUP214 status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

PBX1 is an inclusion eligibility criterion in 2 clinical trials for T-cell prolymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain PBX1 status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains RPN1 status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

TCF3 is an inclusion eligibility criterion in 2 clinical trials for T-cell prolymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain TCF3 status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [3].

TP53 is altered in 25.0% of T-cell prolymphocytic leukemia patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].